Skip to main content

Lymphoproliferative Disorder clinical trials at UC Davis
2 research studies open to eligible people

  • A Study of Experimetnal Tabelecleucel After Failed Standard Treatment for Solid Organ Transplants With Epstein-Barr Virus

    open to all eligible people

    The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

    Sacramento, California and other locations

  • EVERYCHILD PROTOCOL

    “A REGISTRY, ELIGIBILITY SCREENING, BIOLOGY AND OUTCOME STUDY”

    open to eligible people ages up to 25 years

    This research trial studies the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

    Sacramento, California and other locations

Last updated: